IDO expression by dendritic cells: Tolerance and tryptophan catabolism

Nature Reviews Immunology

Volumn 4, Issue 10, 2004, Pages 762-774

  Mellor, Andrew L ^a   Munn, David H ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GAMMA INTERFERON; HYBRID PROTEIN; INDOLEAMINE 2,3 DIOXYGENASE; TRYPTOPHAN;

ALLOGRAFT; AMINO ACID METABOLISM; ANTIGEN PRESENTING CELL; AUTOIMMUNE DISEASE; CATABOLISM; CELL ACTIVATION; CELL SUBPOPULATION; CELL TRANSFER; CELLULAR IMMUNITY; CLINICAL TRIAL; CYTOKINE PRODUCTION; DENDRITIC CELL; ENZYME ACTIVITY; ENZYME MECHANISM; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE THERAPY; GENETIC TRANSFECTION; GRAFT REJECTION; HOST RESISTANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; INFECTION; INFLAMMATION; NONHUMAN; PREGNANCY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; RHEUMATOID ARTHRITIS; STRUCTURAL GENE; T LYMPHOCYTE ACTIVATION; TUBEROUS SCLEROSIS; TUMOR RESISTANCE;

ANIMALS; DENDRITIC CELLS; HUMANS; IMMUNE TOLERANCE; IMMUNOSUPPRESSION; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; MODELS, IMMUNOLOGICAL; TRYPTOPHAN; TRYPTOPHAN OXYGENASE;

EID: 5044220930     PISSN: 14741733     EISSN: None     Source Type: Journal    
DOI: 10.1038/nri1457     Document Type: Review

References (151)

1. Uhlig, H. H. & Powrie, F. Dendritic cells and the intestinal bacterial flora: a role for localized mucosal immune responses. J. Clin. Invest. 112, 648-651 (2003).
2. Sotomayor, E. M. et al. Cross-presentation of tumor antigens by bone marrow-derived antigen-presenting cells is the dominant mechanism in the induction of T-cell tolerance during B-Cell lymphoma progression. Blood 98, 1070-1077 (2001).
3. Moser, M. Dendritic cells in immunity and tolerance - do they display opposite functions? Immunity 19, 5-8 (2003).
4. Hackstein, H. & Thomson, A. W. Dendritic cells: emerging pharmacological targets of immunosuppressive drugs. Nature Rev. Immunol. 4, 24-34 (2004).
5. Mosmann, T. R. & Livingstone, A. M. Dendritic cells: the immune information management experts. Nature Immunol. 5, 564-566 (2004).
6. Bendelac, A. & Medzhitov, R. Adjuvants of immunity: harnessing innate immunity to promote adaptive immunity. J. Exp. Med. 195, F19-F23 (2002).
7. Steinman, R. M., Hawiger, D. & Nussenzweig, M. C. Tolerogenic dendritic cells. Annu. Rev. Immunol. 21, 685-711 (2003).
8. Medzhitov, R. & Janeway, C. A., Jr. Decoding the patterns of self and nonself by the innate immune system. Science 296, 298-300 (2002).
9. + T cell tolerance. Immunity 18, 713-720 (2003).
10. + T cell tolerance. J. Exp. Med. 196, 1627-1638 (2002).
11. Chen, W., Frank, M. E., Jin, W. & Wahl, S. M. TGF-β released by apoptotic T cells contributes to an immunosuppressive milieu. Immunity 14, 715-725 (2001).
12. Powrie, F. & Maloy, K. J. Immunology. Regulating the regulators. Science 299, 1030-1031 (2003).
13. Fairchild, P. J. & Waldmann, H. Dendritic cells and prospects for transplantation tolerance. Curr. Opin. Immunol. 12, 528-535 (2000).
14. Taylor, M. W. & Feng, G. Relationship between interferon-γ, indoleamine 2,3-dioxygenase, and tryptophan catabolism. FASEB J. 5, 2516-2522 (1991).
15. Mellor, A. L. & Munn, D. H. Tryptophan catabolism and T-cell tolerance: immunosuppression by starvation? Immunol. Today 20, 469-473 (1999).
16. Munn, D. H. et al. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 281, 1191-1193 (1998). This report shows that IDO activity inhibits a T-cell-mediated process in mice; in this case maternal T-cell immunity to fetal alloantigens during pregnancy.
17. Mellof, A. L., Keskin, D. B., Johnson, T., Chandler, P. & Munn, D. H. Cells expressing indoleamine 2,3 dioxygenase inhibit T cell responses. J. Immunol. 168, 3771-3776 (2002).
18. Friberg, M. et al. Indoleamine 2,3-dioxygenase contributes to tumor cell evasion of T cell-mediated rejection. Int. J. Cancer 101, 151-155 (2002). References 18 and 19 show that IDO activity can suppress antitumour immunity, challenging previous notions that IDO activity is exclusively an innate host defence mechanism against tumours.
19. Uyttenhove, C. et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nature Med. 9, 1269-1274 (2003).
20. Munn, D. H. et al. Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. J. Clin. Invest. 114, 280-290 (2004). This report identifies specific DC subsets in mice that express IDO, accumulate in tumour-draining lymph nodes and mediate potent T-cell suppression.
21. Grohmann, U. et al. A defect in tryptophan catabolism impairs tolerance in nonobese diabetic mice. J. Exp. Med. 198, 153-160 (2003).
22. Grohmann, U. et al. CTLA-4-Ig regulates tryptophan catabolism in vivo. Nature Immunol. 3, 1097-1101 (2002). This paper indicates that ligation of CD80/CD86 is an alternative mechanism to induce functional IDO-expression by mouse DCs and showed that a component of CTLA4-immunoglobulin-mediated inhibition of allograft rejection was IDO dependent
23. Sakurai, K., Zou, J., Tschetter, J., Ward, J. & Shearer, G. Effect of indoleamine 2,3-dioxygenase on induction of experimental autoimmune encephalomyelitis. J. Neuroimmunol. 129, 186-196 (2002).
24. Gurtner, G. J., Newberry, R. D., Schloemann, S. R., McDonald, K. G. & Stenson, W. F. Inhibition of indoleamine 2,3-dioxygenase augments trinitrobenzene sulfonic acid colitis in mice. Gastroenterology 125, 1762-1773 (2003).
25. + cells modulate pulmonary immune responses by production of indoleamine 2,3-dioxygenase. Am. J. Respir. Cell Mol. Biol. 30, 311-318 (2004).
26. Hayashi, T. et al. Inhibition of experimental asthma by indoleamine 2,3-dioxygenase. J. Clin. Invest. 114, 270-279 (2004).
27. Grohmann, U., Fallarino, F. & Puccetti, P. Tolerance, DCs and tryptophan: much ado about IDO. Trends Immunol. 24, 242-248 (2003).
28. Stone, T. W. & Darlington, L. G. Endogenous kynurenines as targets for drug discovery and development. Nature Rev. Drug Discov. 1, 609-620 (2002).
29. Suzuki, T. et al. Comparison of the sequences of Turbo and Sulculus indoleamine dioxygenase-like myoglobin genes. Gene 308, 89-94 (2003).
30. Dai, W. & Gupta, S. L. Regulation of indoleamine 2,3-dioxygenase gene expression in human fibroblasts by interferon-γ. J. Biol. Chem. 265, 19871-19877 (1990).
31. Hassanain, H. H., Chon, S. Y. & Gupta, S. L. Differential regulation of human indoleamine 2,3-dioxygenase gene expression by interferons-γ and -α. Analysis of the regulatory region of the gene and identification of an interferon-γ-inducible DNA-binding factor. J. Biol. Chem. 268, 5077-5084 (1993).
32. Burke, F., Knowles, R. G., East, N. & Balkwill, F. R. The role of indoleamine 2,3-dioxygenase in the anti-tumour activity of human interferon-γ in vivo. Int. J. Cancer 60, 115-122 (1995).
33. Varga, J., Yufit, T., Hitraya, E. & Brown, R. R. Control of extracellular matrix degradation by interferon-γ. The tryptophan connection. Adv. Exp. Med Biol. 398, 143-148 (1996).
34. Munn, D. H. et al. Inhibition of T cell proliferation by macrophage tryptophan catabolism. J. Exp. Med. 189, 1363-1372 (1999). This report identifies tryptophan depletion due to IDO upregulation in human macrophages as a mechanism to inhibit T cell proliferation.
35. Hwu, P. et al. Indoleamine 2,3-dioxygenase production by human dendritic cells results in the inhibition of T cell proliferation. J. Immunol. 164, 3596-3599 (2000). These authors show that human DCs also mediate IDO-dependent T-cell suppression.
36. Chon, S. Y., Hassanain, H. H. & Gupta, S. L. Cooperative role of interferon regulatory factor 1 andp91 (STAT1) response elements in intereron-γ-inducible expression of human indoleamine 2,3-dioxygenase gene. J. Biol. Chem. 271, 17247-17252 (1996).
37. Silva, N. M. et al. Expression of indoleamine 2,3-dioxygenase, tryptophan degradation, and kynurenine formation during in vivo infection with Toxoplasma gondii: induction by endogenous γ interferon and requirement of interferon regulatory factor 1. Infect. Immun. 70, 859-868 (2002).
38. Babcock, T. A. & Carlin, J. M. Transcriptional activation of indoieamine dioxygenase by interleukin 1 and tumor necrosis factor α in interferon-treated epithelial cells. Cytokine 12, 588-594 (2000).
39. Robinson, C. M., Shirey, K. A. & Carlin, J. M. Synergistic transcriptional activation of indoleamine dioxygenase by IFN-γ and tumor necrosis factor-α. J. Interferon Cytokine Res. 23, 413-421 (2003).
40. Fujigaki, S. et al. Lipoporysaccharide induction of indoleamine 2,3-dioxygenase is mediated dominantly by an IFN-γ-independent mechanism. Eur. J. Immunol. 31, 2313-2318 (2001).
41. Yuan, W., Collado-Hidalgo, A., Yufit, T., Taylor, M. & Varga, J. Modulation of cellular tryptophan metabolism in human fibroblasts by transforming growth factor-β: selective inhibition of indoleamine 2,3-dioxygenase and tryptophanyl-tRNA synthetase gene expression. J. Cell. Physiol. 177, 174-186 (1998).
42. MacKenzie, C. R., Gonzalez, R. G., Kniep, E., Roch, S. & Daubener, W. Cytokine mediated regulation of interferon-γ-induced IDO activation. Adv. Exp. Med. Biol. 467, 533-539 (1999).
43. Fallarino, F. et al. Modulation of tryptophan catabolism by regulatory T cells. Nature Immunol. 4, 1206-1212 (2003). This report shows that T cells expressing CTLA4 induce IDO expression by DCs.
44. Mellor, A. L. et al. Cutting edge: induced indoleamine 2,3 dioxygenase expression in dendritic cell subsets suppresses T cell clonal expansion. J. Immunol. 171, 1652-1655 (2003). This paper shows that specific DC subsets in mouse spleens mediate dominant IDO-dependent T-cell suppression in vivo following ligation of CD80/CD36.
45. + T cells triggers indoleamine 2,3-dioxygenase activity in dendritic cells. J. Immunol. 172, 4100-4110 (2004).
46. + T cells are shown to depend on their ability to induce functional IDO expression by specific DC subsets from mouse spleens through CD80/CD86 ligation.
47. Finger, E. B. & Bluestone, J. A. When ligand becomes receptor - tolerance via B7 signaling on DCs. Nature Immunol. 3, 1056-1057 (2002).
48. Kudo, Y., Boyd, C. A., Sargent, I. L. & Redman, C. W. Tryptophan degradation by human placental indoleamine 2,3-dioxygenase regulates lymphocyte proliferation. J. Physiol. 535, 207-215 (2001).
49. Kudo, Y. & Boyd, C. A. Human placental indoleamine 2,3-dioxygenase: cellular localization and characterization of an enzyme preventing fetal rejection. Biochim. Biophys. Acta 1500, 119-124 (2000).
50. Kudo, Y. et al. Indoleamine 2,3-dioxygenase: distribution and function in the developing human placenta. J. Reprod. Immunol. 61, 87-98 (2004).
51. Honig, A. et al. Indoleamine 2,3-dioxygenase (IDO) expression in invasive extravillous trophoblast supports role of the enzyme for matemo-fetal tolerance. J. Reprod. Immunol. 61, 79-66 (2004).
52. Baban, B. et al. Indoleamine 2,3-dioxygenase expression is restricted to fetal trophoblast giant cells during murine gestation and is maternal genome specific. J. Reprod. Immunol. 61, 67-77 (2004).
53. Mackler, A. M., Barber, E. M., Takikawa, O. & Pollard, J. W. Indoleamine 2,3-dioxygenase is regulated by IFN-γ in the mouse placenta during Listeria monocytogenes infection. J. Immunol. 170, 823-830 (2003).
54. Takikawa, O., Yoshida, R., Kido, R. & Hayaishi, O. Tryptophan degradation in mice initiated by indoleamine 2,3-dioxygenase. J. Biol. Chem. 261, 3648-3653 (1986).
55. Yoshida, R. et al. Regulation of indoleamine 2,3-dioxygenase activity in the small intestine and the epididymis of mice. Arch. Biochem. Biophys. 203, 343-351 (1980).
56. Yoshida, R., Urade, Y., Nakata, K., Watanabe, Y. & Hayashi, O. Specific induction of indoleamine 2,3-dioxygenase by bacterial lipopolysaccharide in the mouse lung. Arch. Biochem. Biophys. 212, 629-637 (1981).
57. + dendritic cells. Int. Immunol. 14, 65-68 (2002).
58. Thomas, S. R. et al. Antioxidants inhibit indoleamine 2,3-dioxygenase in IFN-γ-activated human macrophages: posttranslational regulation by pyrrolidine dithiocarbamate. J. Immunol. 166, 6332-6340 (2001).
59. Aitken, J. B. et al. Determination of the nature of the heme environment in nitrosyl indoleamine 2,3-dioxygenase using multiple-scattering analyses of X-ray absorption fine structure. Biochemistry 43, 4892-4898 (2004).
60. Hucke, C., Mackenzie, C. R., Adjogble, K. D. Z., Takikawa, O. & Daubener, W. Nitric oxide-mediated regulation of γ-interferon-induced bacteriosis: inhibition of degradation of human indoleamine 2,3-dioxygenase. Infect. Immun. 72, 2723-2730 (2004).
61. Pfefferkorn, E. R. Interferon-γ blocks the growth of Toxoplasma gondii in human fibroblasts by inducing the host cells to degrade tryptophan. Proc. Natl Acad. Sci. USA 81, 908-912 (1984).
62. Carlin, J. M., Borden, E. C., Sondel, P. M. & Byme, G. I. Interferon-induced indoleamine 2,3-dioxygenase activity in human mononuclear phagocytes. J. Leukoc. Biol. 45, 29-34 (1989).
63. Gupta, S. L. et al. Antiparasitic and antiproliferative effects of indoleamine 2,3-dioxygenase enzyme expression in human fibroblasts. Infect Immun. 62, 2277-2284 (1994).
64. MacKenzie, C. R., Hadding, U. & Daubener, W. Interferon-γ- induced activation of indoleamine 2,3-dioxygenase in cord blood monocyte-derived macrophages inhibits the growth of group B streptococci. J. Infect. Dis. 178, 875-878 (1998).
65. Hayashi, T. et al. Enhancement of innate immunity against Mycobacterium avium infection by immunostimulatory DNA is mediated by indoleamine 2,3-dioxygenase. Infect. Immun. 69, 6156-6164 (2001).
66. Bodaghi, B. et al. Role of IFN-γ-induced indoleamine 2,3 dioxygenase and inducible nitric oxide synthase in the replication of human cytomegalovirus in retinal pigment epithelial cells. J. Immunol. 162, 957-964 (1999).
67. Adams, O. et al. Role of indoleamine-2,3-dioxygenase in α/β and γ-interferon-mediated antiviral effects against herpes simplex virus infectons. J. Virol. 78, 2632-2636 (2004).
68. Fujigaki, S. et al. L-tryptophan-L-kynurenine pathway metabolism accelerated by Toxoplasma gondii infection is abolished in γ-interferon- gene-deficient mice: cross-regulation between inducible nitric oxide synthase and indoleamine-2,3-dioxygenase. Infect. Immun. 70, 779-786 (2002).
69. Rottenberg, M. E. et al. Regulation and role of IFN-γ in the innate resistance to infection with Chlamydia pneumoniae. J. Immunol. 164, 4812-1818 (2000).
70. Widner, B., Weiss, G. & Fuchs, D. Tryptophan degradation to control T-cell responsiveness. Immunol. Today 21, 250 (2000).
71. Rogers, K. A. et al. Type 1 and type 2 responses to Leishmania major. FEMS Microbiol. Lett, 209, 1-7 (2002).
72. Cady, S. G. & Sono, M. 1-methyl-DL-tryptophan, β-(3- benzofuranyl)-DL-alanine (the oxygen analog of tryptophan), and β-[3-benzo(b)thienyi]-DL-alanine (the sulfur analog of tryptophan) are competitive inhibitors for indoleamine 2,3-dioxygenase. Arch. Biochem. Biophys. 291, 326-333 (1991).
73. Mellor, A. L. et al. Prevention of T cell-driven complement activation and inflammation by tryptophan catabolism during pregnancy. Nature Immunol. 2, 64-68 (2001).
74. Alexander, A. M. et al. Indoleamine 2,3-dioxygenase expression in transplanted NOD islets prolongs graft survival after adoptive transfer of diabetogenic splenocytes. Diabetes 51, 356-365 (2002).
75. Munn, D. H. et al. Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase. Science 297, 1867-1870 (2002).
76. Summers, K. L., Hock, B. D., McKenzie, J. L. & Hart, D. N. Phenotypic characterization of five dendritic cell subsets in human tonsils. Am. J. Pathol. 159, 285-295 (2001).
77. Rissoan, M. C. et al. Subtractive hybridization reveals the expression of immunoglobulin-like transcript 7, Eph-B1, granzyrne B, and 3 novel transcripts in human plasmacytoid dendritic cells. Blood 100, 3295-3303 (2002).
78. + subset. J. Immunol. 165, 1357-1363 (2000). This report identifies IDO as a mechanism used by mouse regulatory DCs.
79. Grohmann, U. et al. CD40 ligation ablates the tolerogenic potential of lymphoid dendritic cells. J. Immunol. 166, 277-283 (2001).
80. Grohmann, U. et al. IL-6 inhibits the tolerogenic function of CD8α- dendritic cells expressing indoleamine 2,3-dioxygenase. J. Immunol. 167, 708-714 (2001).
81. Grohmann, U. et al. Functional plasticity of dendritic cell subsets as mediated by CD40 versus B7 activation. J. Immunol. 171, 2581-2587 (2003). This report shows that IDO-mediated suppression can be upregulated or downregulated by signals from the immune system.
82. + dendritic cells only after microbial stimulus. J. Exp. Med. 196, 1307-1319 (2002).
83. + dendritic cells endowed with type 1 interferon production capacity and tolerogenic potential. Blood 100, 383-390 (2002).
84. Aluvihare, V. R., Kallikourdis, M. & Betz, A. G. Regulatory T cells mediate maternal tolerance to the fetus. Nature Immunol. 5, 266-271 (2004).
85. Barcelo-Batllori, S. et al. Proteomic analysis of cytokine induced proteins in human intestinal epithelial cells: implications for inflammatory bowel diseases. Proteomics 2, 551-560 (2002).
86. Varga, J., Yuft, T. & Brown, R. R. Inhibition of collagenase and stromelysin gene expression by interferon-γ in human dermal fibroblasts is mediated in part via induction of tryptophan degradation. J. Clin. Invest. 96, 475-481 (1995).
87. Meisel, R. et al. Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood 103, 4619-4621 (2004).
88. von Bubnoff, D. et al. FcεRI induces the tryptophan degradation pathway invoted in regulating T cell responses. J. Immunol. 169, 1810-1816 (2002).
89. Lee, G. K. et al. Tryptophan deprivation sensitizes activated T cells to apoptosis prior to cell division. Immunology 107, 1-9 (2002).
90. Fallarino, F. et al. T cell apoptosis by tryptophan catabolism. Cell Death Differ. 9, 1069-1077 (2002). This report indicates that certain T cells are sensitive to the toxic effects of tryptophan metabolites that can be produced by cells expressing IDO.
91. Frumento, G. et al. Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase. J. Exp. Med. 196, 459-468 (2002).
92. Terness, P. et al. Inhibition of allogeneic T cell proliferation by indoleamine 2,3-dioxygenase-expressing dendritic cells: mediation of suppression by tryptophan metabolites. J. Exp. Med. 196, 447-457 (2002).
93. Seman, M. et al. NAD-induced T cell death: ADP-ribosylation of cell surface proteins by ART2 activates the cytolytic P2X7 purinoceptor. Immunity 19, 571-582 (2003).
94. Moffett, J. R. & Namboodiri, M. A. Tryptophan and the immune response. Immunol. Cell Biol. 81, 247-265 (2003).
95. Zhang, P. et al. The GCN2 elF2α kinase is required for adaptation to amino acid deprivation in mice. Mol. Cell. Biol. 22, 6681-6688 (2002).
96. Harding, H. P. et al. Regulated translation initiation controls stress-induced gene expression in mammalian cells. Mol. Cell 6, 1099-1108 (2000).
97. Rohde, J., Heitman, J. & Cardenas, M. E. The TOR kinases link nutrient sensing to cell growth. J. Biol. Chem. 276, 9583-9586 (2001).
98. Gao, X. et al. Tsc tumour suppressor proteins antagonize amino-acid-TOR signaling. Nature Cell Biol. 4, 699-704 (2002).
99. Marshall, B., Keskin, D. B. & Mellor, A. L. Regulation of prostaglandin synthesis and cell adhesion by a tryptophan catabolizing enzyme. BMC Biochem. 2, 5 (2001).
100. van Wissen, M., Snoek, M., Smids, B., Jansen, H. M. & Lutter, R. IFN-γ amplifies IL-6 and IL-8 responses by airway epithelial-like cells via indoleamine 2,3-dioxygenase. J. Immunol. 169, 7039-7044 (2002).
101. Li, Y., Tredget, E, E. & Ghahary, A. Cell surface expression of MHC class I antigen is suppressed in indoleamine 2,3-dioxygenase genetically modified keratinocytes: implications in allogeneic skin substitute engraftment. Hum. Immunol. 65, 114-123 (2004).
102. Waldmann, H. & Cobbold, S. Exploiting tolerance processes in transplantation. Science 305, 209-212 (2004).
103. Munn, D. H. & Mellor, A. L. Macrophages and the regulation of self-reactive T cells. Curr. Pharm. Des. 9, 257-264 (2003).
104. + T cells: role of TGF-β1. J. Immunol. 170, 5897-5911 (2003).
105. Fillatreau, S., Sweenie, C. H., McGeachy, M. J., Gray, D. & Anderton, S. M. B cells regulate autoimmunity by provision of IL-10. Nature Immunol. 3, 944-950 (2002).
106. + regulatory T cells by targeting of antigens to immature dendritic cells, Blood 101, 4862-4869 (2003).
107. + DC, with a plasmacytoid phenotype, induce differentiation and support function of T cells with regulatory properties. Immunology 108, 481-492 (2003).
108. Wakkach, A. et al. Characterization of dendritic cells that induce tolerance and T regulatory 1 cell differentiation in vivo. Immunity 18, 605-617 (2003).
109. + T regulatory cells that can suppress ongoing experimental autoimmune encephalomyelitis. J. Immunol. 172, 1991-1995 (2004).
110. Gilliet, M. & Liu, Y. J. Generation of human CD8 T regulatory cells by CD40 ligand-activated plasmacytoid dendritic cells. J. Exp. Med. 195, 695-704 (2002).
111. Bluestone, J. A. & Abbas, A. K. Natural versus adaptive regulatory T cells. Nature Rev. Immunol. 3, 253-257 (2003).
112. + T regulatory cells. Nature Immunol. 4, 337-342 (2003).
113. Bilsborough, J. & Viney, J. L. Getting to the guts of immune regulation. Immunology 106, 139-143 (2002).
114. + regulatory T cells and their ligands: implications for immunotherapy. Immunity 20, 107-118 (2004).
115. Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J. & Schreiber, R. D. Cancer immunoediting: from immunosurveillance to tumor escape. Nature Immunol. 3, 991-998 (2002).
116. Pardoll, D. Does the immune system see tumors as foreign or self? Annu. Rev. Immunol. 21, 807-839 (2003).
117. Logan, G. J. et al. HeLa cells cocultured with peripheral blood lymphocytes acquire an immuno-inhibitory phenotype through upregulation of indoleamine 2,3-dioxygenase activity. Immunology 105, 478-487 (2002).
118. Huang, A. Y. et al. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science 264, 961-965 (1994).
119. Spiotto, M. T. et al. Increasing tumor antigen expression overcomes 'ignorance' to solid tumors via crosspresentation by bone marrow-derived stromal cells. Immunity 17, 737-747 (2002).
120. Lee, J. R. et al. Pattern of recruitment of immunoregulatory antigen-presenting cells in malignant melanoma. Lab. Invest. 83, 1457-1466 (2003).
121. Hartmann, E. et al. Identification and functional analysis of tumor-infiltrating plasmacytoid dendritic cells in head and neck cancer. Cancer Res. 63, 6478-6487 (2003).
122. Vermi, W. et al. Recruitment of immature plasmacytoid dendritic cells (plasmacytoid monocytes) and myeloid dendritic cells in primary cutaneous melanomas. J. Pathol. 200, 255-268 (2003).
123. Zou, W. et al. Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells. Nature Med. 7, 1333-1346 (2001).
124. Grant, R. S. et al. Induction of indoleamine 2,3-dioxygenase in primary human macrophages by human immunodeficiency virus type 1 is strain dependent. J. Virol. 74, 4110-4115 (2000).
125. Burudi, E. M. et al. Regulation of indoleamine 2,3-dioxygenase expression in simian immunodeficiency virus-infected monkey brains. J. Virol. 76, 12233-12241 (2002).
126. Heyes, M. P. et al. Sources of the neurotoxin quinolinic acid in the brain of HIV-1-infected patients and retrovirus-infected macaques. FASEB J. 12, 881-896 (1998).
127. Kerr, S. J. et al. Kynurenine pathway inhibition reduces neurotoxicity of HIV-1-infected macrophages. Neurology 49, 1671-1681 (1997).
128. Fuchs, D. et al. Immune actuation and decreased tryptophan in patients with HIV-1 infection. J. Interferon Res. 10, 599-603 (1990).
129. Zangerle, R. et al. Effective antiretroviral therapy reduces degradation of tryptophan in patients with HIV-1 infection. Clin. Immunol. 104, 242-247 (2002).
130. Garber, K. Make or break for co-stimulatory blockers. Nature Biotechnol. 22, 145-147 (2004).
131. Kremer, J. M. et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4-Ig. N. Engl. J. Med. 349, 1907-1915 (2003).
132. + regulatory cells? Immunity 14, 399-406 (2001).
133. Frolova, L. Y., Grigorieva, A. Y., Sudomoina, M. A. & Kisselev, L. L. The human gene encoding tryptophanyl-tRNA synthetase: interferon-response elements and exon-intron organization. Gene 128, 237-245 (1993).
134. Fleckner, J., Martensen, P. M., Tolstrup, A. B., Kjeldgaard, N. O. & Justesen, J. Differential regulation of the human, interferon inducible tryptophanyl-tRNA synthetase by various cytokines in cell lines. Cytokine 7, 70-77 (1995).
135. Tatsumi, K. et al. Induction of tryptophan 2,3-dioxygenase in the mouse endometrium during implantation. Biochem. Biophys. Res. Commun. 274, 166-170 (2000).
136. Suzuki, S. et al. Expression of indoleamine 2,3-dioxygenase and tryptophan 2,3-dioxygenase in early conception. Biochem. J. 355, 425-429 (2001).
137. Werner-Felmayer, G. et al. Characteristics of interferon induced tryptophan metabolism in human cells in vitro. Biochim. Biophys. Acta 1012, 140-147 (1989).
138. Ottaviani, E. & Franceschi, C. The invertebrate phagocytic immunocyte:clues to a common evolution of immune and neuroendocrine systems. Immunol. Today 18, 169-174 (1997).
139. Guilbert, L., Robertson, S. A. & Wegmann, T. G. The trophoblast as an integral component of a macrophage-cytokine network. Immunol. Cell Biol. 71, 49-57 (1993).
140. Guleria, I. & Pollard, J. W. The trophoblast is a component of the innate immune system during pregnancy. Nature Med. 6, 583-593 (2000).
141. Grolleau, A. et al. Global and specific translational control by rapamycin in T cells uncovered by microarrays and proteomics. J. Biol. Chem. 277, 22175-22184 (2002).
142. Harding, H. P. et al. An integrated stress response regulates amino acid metabolism and resistance to oxidatrve stress. Mol. Cell 11, 619-633 (2003).
143. Calkhoven, C. F., Muller, C. & Leute, A. Translational control of gene expression and disease. Trends Mol. Med. 8, 577-583 (2002).
144. Garcia-Sanz, J. A., Mikulis, W., Livingstone, A., Lefkovits, I. & Mullner, E. W. Translational control: a general mechanism for gene regulation during T cell activation. FASEB J. 12, 299-308 (1998).
145. Chiarugi, A., Rovida, E., Dello Sbarba, P. & Moroni, F. Tryptophan availability selectivery limits NO-synthase induction in macrophages. J. Leukoc. Biol. 73, 172-177 (2003).
146. Mahnke, K., Knop, J. & Enk, A. H. Induction of tolerogenic DCs: 'you are what you eat'. Trends Immunol. 24, 646-651 (2003).
147. + T-helper and a T-killer cell. Nature 393, 474-478 (1998).
148. Alpan, O., Bachelder, E., Isil, E., Arnheiter, H. & Matzinger, P. 'Educated' dendritic cells act as messengers from memory to naive T helper cells. Nature Immunol. 5, 615-622 (2004).
149. Thomas, S. R. & Stocker, R. Antioxidant activities and redox regulation of interferon-γ-induced tryptophan metabolism in human monocytes and macrophages. Adv. Exp. Med. Biol. 467, 541-552 (1999).
150. Mellor, A. L. & Munn, D. H. Tryptophan catabolism prevents maternal T cells from activating lethal anti-fetal immune responses. J. Reprod. Immunol. 52, 5-13 (2001).
151. Miki, T. et al. Blockade of tryptophan catabolism prevents spontaneous tolerogenidty of liver allografts. Trans. Proc. 33, 129-130 (2001).